Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck
Stock Ownership - Kite Pharma
F. Stephen Hodi
Consultant or Advisory Role - Merck
Research Funding - Merck
Richard Kefford
Consultant or Advisory Role - Merck
Honoraria - Merck
Other Remuneration - Merck
Omid Hamid
Consultant or Advisory Role - Merck
Research Funding - Merck
Adil Daud
Consultant or Advisory Role - Merck; Oncoscience
Research Funding - Merck
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck
Wen-Jen Hwu
Consultant or Advisory Role - Merck; Novartis
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck
Tara C. Gangadhar
No relevant relationships to disclose
Amita Patnaik
Research Funding - Merck
Anthony M. Joshua
Consultant or Advisory Role - Merck
Peter Hersey
No relevant relationships to disclose
Jeffrey S. Weber
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Roxana Stefania Dronca
No relevant relationships to disclose
Hassane M. Zarour
No relevant relationships to disclose
Kevin Gergich
Employment or Leadership Position - Merck
Stock Ownership - Merck
Xiaoyun (Nicole) Li
Employment or Leadership Position - Merck
Stock Ownership - Merck
Robert Iannone
Employment or Leadership Position - Merck
Stock Ownership - Merck
Soonmo Peter Kang
Employment or Leadership Position - Merck
Scot Ebbinghaus
Employment or Leadership Position - Merck
Stock Ownership - Merck
Caroline Robert
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche